BCRX vs. HALO, MDGL, ALKS, IONS, FOLD, LGND, DVAX, GERN, CLDX, and MNKD
Should you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), Geron (GERN), Celldex Therapeutics (CLDX), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.
BioCryst Pharmaceuticals vs.
Halozyme Therapeutics (NASDAQ:HALO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.
Halozyme Therapeutics has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics received 41 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 69.53% of users gave Halozyme Therapeutics an outperform vote while only 66.67% of users gave BioCryst Pharmaceuticals an outperform vote.
Halozyme Therapeutics has a net margin of 43.74% compared to BioCryst Pharmaceuticals' net margin of -30.01%. Halozyme Therapeutics' return on equity of 157.78% beat BioCryst Pharmaceuticals' return on equity.
Halozyme Therapeutics presently has a consensus price target of $62.78, indicating a potential upside of 8.95%. BioCryst Pharmaceuticals has a consensus price target of $15.50, indicating a potential upside of 68.62%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Halozyme Therapeutics.
Halozyme Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.
In the previous week, Halozyme Therapeutics had 28 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 36 mentions for Halozyme Therapeutics and 8 mentions for BioCryst Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 0.74 beat BioCryst Pharmaceuticals' score of 0.15 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Halozyme Therapeutics beats BioCryst Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get BioCryst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCryst Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:BCRX) was last updated on 2/21/2025 by MarketBeat.com Staff
Free BCRX Stock Alerts